WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 9, 2005--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that its lead product candidate, the oral HIV maturation inhibitor PA-457, will be the subject of two oral presentations at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held December 16-19, 2005 in Washington, DC.
